Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Patent
1996-08-15
1998-02-03
McKane, Joseph
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
544 35, 544102, 544104, 544244, 544262, 544264, 544267, 544277, 544299, 544309, 544311, 544313, 544314, 544317, 544335, 548112, 5483147, 5483611, 5483615, 5483621, 5483625, 5483641, 548412, 548413, 548414, 548440, 548441, C07F 902, C07D20708, C07D20710
Patent
active
057146063
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention is directed to pyrrolidine monomeric units and to oligomers constructed from them. The oligomers can be synthesized to have either random or predefined sequences of monomeric units and can be joined via phosphate linkages, including phosphorothioate, phosphodiester and phosphoramidate linkages. Each of the monomeric units can include a chemical moiety thereon for binding of the oligomeric structures to proteins, nucleic acid, and other biological targets. In preferred embodiments, the compounds of the invention act as inhibitors of enzymes such as phospholipase A.sub.2 and are used for the treatment of inflammatory diseases including atopic dermatitis and inflammatory bowel disease.
BACKGROUND OF THE INVENTION
Phospholipases A.sub.2 (PLA.sub.2) are a family of enzymes that hydrolyze the sn-2 ester linkage of membrane phospholipids resulting in release of a free fatty acid and a lysophospholipid (see, Dennis, E. A., The Enzymes, Vol. 16, pp. 307-353, Boyer, P. D., ed., Academic Press, New York, 1983). Elevated levels of type II PLA.sub.2 are correlated with a number of human inflammatory diseases. The PLA.sub.2 -catalyzed reaction is the rate-limiting step in the release of a number of pro-inflammatory mediators. Arachidonic acid, a fatty acid commonly linked at the sn-2 position, serves as a precursor to leukotrienes, prostaglandins, lipoxins and thromboxanes. The lysophospholipid can be a precursor to platelet-activating factor. PLA.sub.2 is regulated by pro-inflammatory cytokines and, thus, occupies a central position in the inflammatory cascade (see, e.g., Dennis, ibid.; Glaser, et al., TiPs Reviews 1992, 14, 92; and Pruzanski, et al., Inflammation 1992, 16, 451).
All mammalian tissues evaluated thus far have exhibited PLA2 activity. At least three different types of PLA.sub.2 are found in humans: pancreatic (type I), synovial fluid (type II) and cytosolic. Studies suggest that additional isoenzymes exist. Type I and type II, the secreted forms of PLA.sub.2, share strong similarity with phospholipases isolated from the venom of snakes. The PLA.sub.2 enzymes are important for normal functions including digestion, cellular membrane remodeling and repair, and in mediation of the inflammatory response. Both cytosolic and type II enzymes are of interest as therapeutic targets. Increased levels of the type II PLA.sub.2 are correlated with a variety of inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and septic shock, suggesting that inhibitors of this enzyme would have therapeutic utility. Additional support for a role of PLA.sub.2 in promoting the pathophysiology observed in certain chronic inflammatory disorders was the observation that injection of type II PLA.sub.2 into the footpad of rats (Vishwanath, et al., Inflammation 1988, 12, 549) or into the articular space of rabbits (Bomalaski, et al., J. Immunol. 199, 146, 3904) produced an inflammatory response. When the protein was denatured before injection, no inflammatory response was produced.
The type II PLA.sub.2 enzyme from synovial fluid is a relatively small molecule (about 14 kD) and can be distinguished from type I enzymes (e.g., pancreatic) by the sequence and pattern of its disulfide bonds. Both types of enzymes require calcium for activity. The crystal structures of secreted PLA.sub.2 enzymes from venom and pancreatic PLA.sub.2, with and without inhibitors, have been reported (Scott, et al., Science 1990, 250, 1541). Recently, the crystal structure of PLA.sub.2 from human synovial fluid has been solved (Wery, et al., Nature 1991, 352, 79). The structures clarify the role of calcium and amino acid residues in catalysis. The calcium acts as a Lewis acid to activate the scissile ester carbonyl and bind the lipid, and a His-Asp side chain dyad acts as general base catalyst to activate a water molecule nucleophile. This is consistent with the absence of any acyl enzyme intermediates, and is also comparable to the catalytic mechanism of serine proteases. The cat
REFERENCES:
patent: 3687808 (1972-08-01), Merigan, Jr. et al.
patent: 5210264 (1993-05-01), Yau
patent: 5218105 (1993-06-01), Cook et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5578718 (1996-11-01), Cook et al.
Achari et al., "Facing up to Membranes: Structure/Function Relationships in Phospholipases," Cold Spring Harbor Symp. Quant. Biol., 52:441-452, 1987.
Agrawal, S., ed., Protocols for Oligonucleotides and Analogs, New Jersey: Humana Press, 1993.
Alul et al., "Oxalyl-CPG: a labile support for synthesis of sensitive oligonucleotide derivatives," Nucleic Acids Research, 19:1527-1532, 1991.
Beaucage et al., "Advances in the Synthesis Oligonucleotides by the Phosphoramidite Approach," Tetrahedron, 48:2223-2311, 1992.
Bodansky, M., Principles of Peptide Synthesis, Springer-Verlag, Berlin, 1984.
Bomalaski et al., "Human Extracellular Recombinant Phospholipase A.sub.2 Induces an Inflammatory Response in Rabbit Joints, " J. Immunol., 146: 3904-3910, 1991.
Bouzard et al., "Fluoronaphthyridines and Quinolones as Antibacterial Agents. 2. Synthesis and Structure-Activity Relationships of New 1-tert-Butyl 7-Substituted Derivatives," J. Med. Chem., 33:1344-1352, 1990.
Braish et al., "Synthesis of (S,S)- and 55:1684-1687, 1990.
Bridges et al., "Conformationally Defined Neurotransmitter Analogues. Selective Inhibition of Glutamate Uptake by One Pyrrolidine-2,4-dicarboxylate Diastereomer," J. Med. Chem., 34:717-725, 1991.
Burack et al., "Role of Lateral Phase Separation in the Modulation of Phospholipase A.sub.2 Activity," Biochemistry, 32:583-589, 1993.
Campbell et al., "Inhibition of Phospholipase A.sub.2 ; a Molecular Recognition Study," J. Chem. Soc., Chem. Commun., 1560-1562, 1988.
Cho et al., "The Chemical Basis for Interfacial Activation of Monomeric Phospholipases A.sub.2," J. Biol. Chem., 263:11237-11241, 1988.
Cooper et al., "A Route to Optically Active Trisubstituted Pyrrolidines using Claisen Rearrangements of Azalactones," Tetrahedron Letters, 28:3031-3034, 1987.
Davidson et al., "1-Stearyl,2-Stearoylaminodeoxy Phosphatidylcholine, A Potent Reversible Inhibitor of Phospholipase A.sub.2," Biochem. Biophyis. Res. Commun., 137:587-592, 1986.
Davidson et al., "Inhibition of Phosphilipase A.sub.2 by Lipocortins and Calpactins, " J. Biol. Chem., 262:1698-1705, 1987.
Dennis et al., "Phospholipases," The Enzymes, Boyer, P.D., ed., New York: Academic Press, 16:307-353, Chapter 9, 1983.
Ecker et al., "Rational screening of oligonucleotide combinatorial libraries for drug discovery," Nucleic Acids Res., 21:1853-1856, 1993.
Englisch et al., "Chemically Modified Oligonucleotides as Probes and Inhibitors," Angewandte Chemie, International Edition, 30:613-722, 1991.
Franson et al., "Phospholipid metabolism by phagocytic cells. Phospholipases A.sub.2 associated with rabbit polymorphonuclear leukocyte granules," J. Lipid Res., 15:380-388, 1974.
Freeman, J.P., ed., "Reduction of alpha-amino Acids: L-Valinol," Organic Syntheses, New York: John Wiley & Sons, Inc., 530-533, 1990.
Gait, M.J, ed., Oligonucleotide Synthesis, A Practical Approach, Oxford: IRL Press, 1984.
Geysen et al., "Strategies for epitope analysis using peptide synthesis," J. Immun. Meth., 102:259-274, 1987.
Glaser et al., "Phospholipase A.sub.2 enzymes: regulation and inhibition," TIPS Review, 14:92-98, 1993.
Grainger et al., "An enzyme caught in action: direct imaging of hydrolytic function and domain formation of phospholipase A.sub.2 in phosphatidylcholine monolayers," FEBS Lett., 252:73-82, 1989.
Green et al., Protective Groups in Organic Synthesis, 2d Ed., New York: John Wiley & Sons, Inc., 1991.
Houghton et al., "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," Nature, 354:84-86, 1991.
Jaeger et al., "Pyrrolidinediols. 1-Substituted 3-Hydroxymethyl-4-hydroxypyrrolidines and Derivatives," J. Organic Chemistry, 30:740-744, 1965.
Jordis et al., "Synthesis of (1R,4R)- and Derivatives," Synthesis, 925-930, 1990.
Kroschwitz, J., ed., "Polyn
Acevedo Oscar L.
Hebert Normand
ISIS Pharmaceuticals Inc.
McKane Joseph
LandOfFree
Pyrrolidine-containing monomers and oligomers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidine-containing monomers and oligomers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine-containing monomers and oligomers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-663581